Prevalence, sex differences, disability burden, and temporal trends of substance use disorders across twenty-two Arab countries, 2019–2023: a secondary analysis of the Global Burden of Disease Study 2023
The Lancet Regional Health - Eastern Mediterranean · 2026
DOI: 10.1016/j.laneme.2026.100002 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Lancet Regional Health - Eastern Mediterranean, 2026. Verfasst von Tarik Qassem und 9 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Comparative epidemiological analyses of substance use disorders across the Arab world remain limited despite variability in sociocultural norms, legal environments, conflict exposure, and health-system capacity. No previous study has examined all Global Burden of Disease (GBD) substance use disorder categories across the 22 Arab League member states by sex and disability burden against an explicit global benchmark.
Methods
We analysed GBD 2023 age-standardised prevalence, disability-adjusted life years (DALYs), and mortality-rate estimates for substance use disorders and seven substance-specific categories across the 22 Arab League member states, by sex, from 2019 to 2023. Regional aggregates were unweighted across-country medians; deviation from the global estimate was expressed as the percentage by which each value fell below or above the GBD 2023 global point estimate.
Findings
In 2023, regional age-standardised substance use disorder prevalence was 0.78% (median 95% UI 0.66–0.89), approximately 63% below the GBD 2023 global estimate of 2.10%. Alcohol use disorder showed the largest divergence: 0.35% (0.26–0.44), 76% below the global estimate. Opioid use disorder was closest to global levels: 0.19% (0.15–0.24), 11% below the global estimate; the global benchmark was exceeded in the United Arab Emirates. Female opioid use disorder prevalence exceeded male prevalence in 19 of the 22 countries. Four countries (Libya, the United Arab Emirates, Morocco, and Algeria) exceeded the global opioid DALY rate.
Interpretation
Burden remains below global levels in most Arab League countries but is not uniformly low, and estimates depend on the quality of primary data input, which varies across countries. Findings could support country-specific planning, sex-disaggregated reporting, targeted opioid agonist therapy, and stronger primary surveillance. Funding None.
Zitieren
APA
Qassem, T., Muneer, A., Ghaferi, H. A., Fayek, M., Elarabi, H., Foad, W., Helmi, S., Tariq, O., Bokhari, S. A., & Singh, D. (2026). Prevalence, sex differences, disability burden, and temporal trends of substance use disorders across twenty-two Arab countries, 2019–2023: a secondary analysis of the Global Burden of Disease Study 2023. The Lancet Regional Health - Eastern Mediterranean. https://doi.org/10.1016/j.laneme.2026.100002
Vancouver
Qassem T, Muneer A, Ghaferi HA, Fayek M, Elarabi H, Foad W, et al. Prevalence, sex differences, disability burden, and temporal trends of substance use disorders across twenty-two Arab countries, 2019–2023: a secondary analysis of the Global Burden of Disease Study 2023. The Lancet Regional Health - Eastern Mediterranean. 2026. doi:10.1016/j.laneme.2026.100002
BibTeX
@article{Qassem2026,
author = {Qassem, Tarik and Muneer, Ahmed and Ghaferi, Hamad Al and Fayek, Mohammad and Elarabi, Hesham and Foad, Wael and Helmi, Sahar and Tariq, Omar and Bokhari, Syed Ali and Singh, Darshan},
title = {Prevalence, sex differences, disability burden, and temporal trends of substance use disorders across twenty-two Arab countries, 2019–2023: a secondary analysis of the Global Burden of Disease Study 2023},
journal = {The Lancet Regional Health - Eastern Mediterranean},
year = {2026},
doi = {10.1016/j.laneme.2026.100002}
}
EUVIMED